

**PHONG PHU PHARMACEUTICAL  
JOINT STOCK COMPANY**

**No.: 07/2025/PP-TCK**

*(Re: Explanation of the Net Profit after income tax  
Discrepancy in the 2025 Audited Reviewed Interim  
Financial Statements)*

**SOCIALIST REPUBLIC OF VIETNAM**

Independence – Freedom – Happiness

***Ho Chi Minh City, Aug. 15th, 2025***

**To: - STATE SECURITIES COMMISSION  
- HANOI STOCK EXCHANGE**

Phong Phu Pharmaceutical Joint Stock Company hereby provides an explanation regarding the discrepancy in Net Profit after income tax in the 2025 Audited Reviewed Interim Financial Statements for the period from January 1, 2025 to June 30, 2025, as follows:

1. The Audited Reviewed Interim Financial Statements for the period from January 1, 2025 to June 30, 2025:
  - Net Profit after income tax for 2025 Interim financial statements: VND 9,437,894,239
  - Net Profit after income tax for 2024 Interim financial statements: VND 7,456,594,814
  - Increase amount : VND 1,981,299,425
  - Increase rate : 26.57%
2. The Audited Reviewed Interim Consolidated Financial Statements for the period from January 1, 2025 to June 30, 2025:
  - Net Profit after income tax for 2025 Interim financial statements: VND 8,845,057,026
  - Net Profit after income tax for 2024 Interim financial statements: VND 7,218,055,838
  - Increase amount : VND 1,627,001,188
  - Increase rate : 22.54%

The primary reason for this increase in profit:

- The Audited Reviewed Interim Financial Statements:
  - + Financial income increased by 116% over to the same period last year
  - + % Cost of goods sold/revenues from sale decreased 1.6% compared to the same period last year.
- The Audited Reviewed Interim Consolidated Financial Statements:
  - + % Cost of goods sold/revenues from sale decreased 3.9% compared to the same period last year.

As a result, the Net Profit after income tax in the 2025 Audited Reviewed Interim financial statements and Audited Reviewed Interim consolidated financial statements is higher than in 2024.

Through this official letter, Phong Phu Pharmaceutical Joint Stock Company reports and explains the matter to the relevant authorities.

Sincerely,

Recipients:

- As stated above;
- Office archives.

**PHONG PHU PHARMACEUTICAL  
JOINT STOCK COMPANY**  
**GENERAL DIRECTOR**



*Chức Năng Ngôn*